European Archives - Page 155 of 1213 - European Medical Journal

Optimising Treatment Strategies for Advanced Melanoma

A new study investigates the combination of nivolumab and hypofractionated radiotherapy in advanced melanoma.

Current Treatment of Advanced Prostate Cancer: The Balance between Efficacy and Safety

Understanding the burden and measurement of pruritus in PBC

Primary biliary cholangitis (PBC) often causes pruritus, impacting QoL. Validated patient-reported outcomes (PROs), such as PBC-40 an WI-NRS, can assess severity and aid management…

EMJ Hepatology 13 [Supplement 1] 2025

In this latest review article, explore the most recent data presented at the 2024 American Association for the Study of Liver Diseases…

Parkinson’s Disease Cases Predicted to Double by 2050: Global Study

Parkinson’s disease cases are set to double by 2050 due to ageing populations. Study highlights urgent need for action.

Advancements in Laparoscopic Surgery for Early Prostate Cancer

Recent research comparing laparoscopic and open radical prostatectomy outcomes shows that radical prostatectomy leads to shorter hospital stays.

Dupilumab Reduces Airway Inflammation in Type 2 Asthma

A Phase IV trial has demonstrated that dupilumab significantly reduces airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma.

Cancer Screening Rates Rebound Post-Pandemic, But Disparities Remain

Explore the rates of screening for breast and colorectal cancer post-pandemic.

Researchers Have Identified Gut Microbiome Ratios Linked to Multiple Sclerosis

Gut microbiome study identifies microbial ratio linked to multiple sclerosis severity, offering potential for diagnostics and therapies.

Beyond Symptom Control: Can We Achieve Deep Remission in Psoriasis?

In this episode, Jonathan Sackier welcomes Andrew Blauvelt, a distinguished dermatologist and leading expert in immunodermatology. They discuss groundbreaking advancements in psoriasis treatment, including the role of high-dose biologics in achieving deep remission and how IL-23 inhibition is transforming long-term disease management.